Tuesday 7th September, 2010 | 4:19 pm

Home | Sitemap | Contact us

Electronic IR Package

Contact

Date
2010-08-13	AKELA Pharma Reports Results for the Second Quarter of Fiscal 2010

2010-03-19	AKELA Pharma Files Restated MD&A for the Fiscal Year 2008

2009-11-16	AKELA Pharma Reports Third Quarter 2009 Financial and Operating Results

2009-11-04	AKELA Expands Drug Formulation and Manufacturing Capabilities with Spray Drying Technology

2009-09-03	AKELA Pharma Announces Restructuring

2009-09-02	AKELA Pharma Announces New Leadership

2009-08-17	Akela Pharma reports results for the second quarter of Fiscal 2009

2009-06-30	Akela announces agreement with Tekes for a payment schedule on grant repayments

2009-06-27	Akela Pharma appoints new board of directors

2009-06-17	Akela announces amendment to Fentanyl TAIFUN(R) license agreement with Teikoku Seiyaku

2009-05-22	Akela Pharma Inc. and Nventa Biopharmaceuticals Corporation (NVN.TO) Announce Closing of Merger

2009-04-24	Akela Pharma Inc. to Buy Nventa Biopharmaceuticals Corporation in Stock Deal Worth C $1.4 Million

2009-03-11	Akela Pharma Announces Settlement Agreement in LAB Research Litigation

2009-02-26	Akela Pharma Signs an Exclusive Development Agreement to Develop Specialized Oral Dosage Forms at its PharmaForm Subsidiary

2009-02-09	Akela Pharma to cut costs to sustain long-term viability of the company

2009-01-13	Akela Pharma announces achievement of third Fentanyl TAIFUN(R) Phase 3

2008-11-14	AKELA PHARMA REPORTS RESULTS FOR THE THIRD QUARTER OF FISCAL 2008

2008-11-06	AKELA PHARMA ANNOUNCES SENIOR MANAGEMENT AND BOARD OF DIRECTORS CHANGES

2008-10-30	AKELA PHARMA ANNOUNCES ACHIEVEMENT OF SECOND OF A SERIES OF THREE FENTANYL TAIFUN® PHASE 3 STUDY RELATED MILESTONES

2008-09-04	AKELA PHARMA ANNOUNCES APPROVAL TO INITIATE FENTANYL TAIFUN® PHASE 3 STUDY IN EUROPE AND INITIATION OF CLINICAL PROGRAM IN JAPAN

2008-06-12	AKELA PHARMA AWARDED DEVELOPMENT CONTRACT FROM PEAR TREE PHARMACEUTICALS, INC. AT ITS PHARMAFORM SUBSIDIARY

2008-06-09	AKELA PHARMA ANNOUNCES AMENDMENTS TO ITS ORIGINAL LICENSING AND DEVELOPMENT AGREEMENT WITH JANSSEN PHARMACEUTICA NV.

2008-06-05	AKELA PHARMA awarded development contract at its pharmaform subsidiary

2008-05-15	AKELA PHARMA REPORTS RESULTS FOR THE FIRST QUARTER OF FISCAL 2008

2008-05-14	AKELA PHARMA WINS BEST ABSTRACT REWARD AT THE 11TH ASIA PACIFIC CONGRESS OF NEPHROLOGY

2008-03-31	AKELA PHARMA REPORTS RESULTS FOR FOURTH QUARTER AND FISCAL 2007

2008-03-27	AKELA PHARMA CLOSES CDN $10.35 MILLION FINANCING

2008-03-25	AKELA PHARMA TO HOLD FOURTH QUARTER AND FISCAL 2007 CONFERENCE CALL AND WEBCAST

2008-03-18	AKELA PHARMA FILES FINAL SHORT FORM PROSPECTUS

2008-03-06	AKELA PHARMA INITIATES ITS FIRST ABUSE DETERRENT OPIOID PHASE I CLINICAL TRIAL

2008-02-25	AKELA PHARMA FILES PRELIMINARY SHORT FORM PROSPECTUS

2008-02-04	AKELA PHARMA RECEIVES LETTER FROM THE FDA REGARDING ITS PRE-CLINICAL TOXICOLOGY STUDIES FOR FENTANYL TAIFUN®

2008-01-03	AKELA PHARMA LICENSES FENTANYL TAIFUN® TO JANSSEN PHARMACEUTICA NV FOR CANADA

2007-12-20	AKELA PHARMA PROVIDES CORPORATE UPDATE

2007-11-12	AKELA PHARMA ANNOUNCES FINAL POSITIVE RESULTS FROM ITS GROWTH HORMONE RELEASING HORMONE (GHRH) PHASE II TRIAL

2007-11-09	AKELA PHARMA REPORTS RESULTS FOR THIRD QUARTER OF FISCAL 2007

2007-10-15	AKELA PHARMA INC. ANNOUNCES U.S. PUBLIC OFFERING AND PROPOSED LISTING

2007-10-09	AKELA PHARMA INC. COMPLETES SHARE CONSOLIDATION

2007-09-05	AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL

2007-07-23	AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL

2007-07-12	LAB INTERNATIONAL ANNOUNCES POSITIVE RESULTS FROM ITS GROWTH HORMONE RELEASING HORMONE (GHRH) PHASE II TRIAL

2007-07-12	LAB INTERNATIONAL ANNOUNCES NAME CHANGE TO AKELA PHARMA INC.

2007-06-21	LAB INTERNATIONAL LICENSES FENTANYL TAIFUN® TO JANSSEN PHARMACEUTICA NV FOR EUROPE

2007-05-15	LAB INTERNATIONAL REPORTS RESULTS FOR FIRST QUARTER OF FISCAL 2007

2007-05-10	LAB INTERNATIONAL TO HOLD FIRST QUARTER 2007 CONFERENCE CALL AND WEBCAST

2007-03-26	LAB INTERNATIONAL REPORTS RESULTS FOR FOURTH QUARTER AND FISCAL 2006

2007-03-20	LAB INTERNATIONAL TO HOLD FOURTH QUARTER AND FISCAL 2006 CONFERENCE CALL AND WEBCAST

2007-03-05	LAB INTERNATIONAL ANNOUNCES POSITIVE RESULTS FROM THE OPEN-LABEL PHASE IIB FENTANYL TAIFUN® TRIAL

2007-02-08	LAB INTERNATIONAL COMPLETES PATIENT ENROLLMENT IN ITS GROWTH HORMONE RELEASING HORMONE (GHRH) PRODUCT PHASE IIA TRIAL

2007-01-31	LAB INTERNATIONAL INITIATES PATIENT ENROLLMENT IN THE EXTENSION OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL

2007-01-25	LAB INTERNATIONAL ANNOUNCES THE CLOSING OF THE PHARMAFORM L.L.C. ACQUISITION

2007-01-11	LAB INTERNATIONAL ANNOUNCES THE SIGNING OF THE DEFINITIVE PURCHASE AND SALE AGREEMENT FOR THE ACQUISITION OF PHARMAFORM L.L.C.

2006-12-05	LAB INTERNATIONAL TO PRESENT AT UPCOMING BMO CAPITAL MARKETS FOCUS ON HEALTHCARE CONFERENCE IN NEW YORK

2006-11-14	LAB INTERNATIONAL REPORTS RESULTS FOR THIRD QUARTER OF FISCAL 2006

2006-11-10	LAB INTERNATIONAL TO HOLD THIRD QUARTER 2006 RESULTS CONFERENCE CALL AND WEBCAST

2006-10-27	LAB INTERNATIONAL ANNOUNCES BOUGHT DEAL FOR ITS RESIDUAL OWNERSHIP POSITION IN LAB RESEARCH INC.

2006-10-26	LAB INTERNATIONAL ANNOUNCES LETTER OF INTENT TO ACQUIRE PHARMAFORM L.L.C.

2006-10-04	LAB INTERNATIONAL REPORTS POSITIVE RESULTS FROM ITS LAB-CGRP PHASE IIA STUDY

2006-09-12	LAB INTERNATIONAL RAISES ADDITIONAL $6.0 MILLION FROM OVER-ALLOTMENT OPTION EXERCISE

2006-08-10	LAB INTERNATIONAL REPORTS RESULTS FOR SECOND QUARTER OF FISCAL 2006

2006-08-09	LAB INTERNATIONAL COMPLETES PATIENT ENROLLMENT IN LAB-CGRP PHASE IIA TRIAL

2006-08-08	LAB INTERNATIONAL TO HOLD SECOND QUARTER 2006 RESULTS CONFERENCE CALL AND WEBCAST

2006-08-03	LAB INTERNATIONAL ANNOUNCES THE CLOSING OF LAB RESEARCH INC. INITIAL PUBLIC OFFERING

2006-07-25	LAB RESEARCH INC., A SUBSIDIARY OF LAB INTERNATIONAL, FILES FINAL PROSPECTUS FOR ITS INITIAL PUBLIC OFFERING

2006-07-12	LAB INTERNATIONAL ANNOUNCES POSITIVE FENTANYL PHASE IIA RESULTS

2006-06-13	LAB INTERNATIONAL INITIATES ENROLLMENT IN PHASE IIB FENTANYL TAIFUN® TRIAL

2006-05-31	LAB RESEARCH INC., A WHOLLY OWNED SUBSIDIARY OF LAB INTERNATIONAL, FILES PRELIMINARY PROSPECTUS FOR ITS INITIAL PUBLIC OFFERING

2006-05-12	LAB INTERNATIONAL REVENUES INCREASES BY MORE THAN 20% IN FIRST QUARTER

2006-04-18	LAB INTERNATIONAL INITIATES PATIENT ENROLLMENT FOR LAB-CGRP PHASE IIA TRIAL

2006-04-03	LAB INTERNATIONAL COMPLETES PATIENT ENROLLMENT IN FENTANYL TAIFUN® PHASE IIA TRIAL

2006-03-16	LAB INTERNATIONAL 2005 REVENUES UP 85% IN YEAR AND 77% IN FOURTH QUARTER

2006-03-06	LAB INTERNATIONAL TO HOLD FOURTH QUARTER AND FISCAL 2005 RESULTS CONFERENCE CALL AND WEBCAST

2006-01-24	LAB INTERNATIONAL ANNOUNCES FINAL CGRP PHASE I PHARMACOKINETIC RESULTS

2006-01-11	LAB INTERNATIONAL LICENSES FENTANYL TAIFUN® FOR JAPAN

2006-01-10	LAB INTERNATIONAL COMMON SHARES ELIGIBLE FOR COVERAGE UNDER QUEBEC SME GROWTH STOCK PLAN

2005-12-13	LAB INTERNATIONAL RAISES $12.3 MILLION IN PRIVATE PLACEMENT

2005-11-08	LAB INTERNATIONAL REVENUES INCREASES BY 70% IN THIRD QUARTER

2005-10-26	LAB INTERNATIONAL ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM ADDITIONAL PHASE I FENTANYL TAIFUN® TRIAL

2005-09-22	LAB INTERNATIONAL COMPLETES PHASE I TRIAL FOR ITS NOVEL ASTHMA PRODUCT, LAB CGRP

2005-07-28	LAB INTERNATIONAL REVENUES INCREASES BY 129% IN SECOND QUARTER

2005-07-05	LAB INTERNATIONAL INITIATES ENROLLEMENT IN PHASE II TRIAL FOR ITS GHRH PRODUCT

2005-06-28	LAB INTERNATIONAL INITIATES ENROLLMENT IN PHASE I TRIAL FOR ITS NOVEL ASTHMA PRODUCT LAB CGRP

2005-05-12	LAB INTERNATIONAL REVENUES UP 66% IN FIRST QUARTER

2005-05-05	LAB INTERNATIONAL TO HOLD SHAREHOLDER’S MEETING MAY 10, 2005 IN MONTREAL

2005-03-29	LAB INTERNATIONAL INITIATES PATIENTS ENROLLMENT IN PHASE II FENTANYL TAIFUN® TRIAL

2005-01-18	LAB INTERNATIONAL RAISES ADDITIONAL $2.4 MILLION

2004-12-30	LAB international announces private placement for approximately $10 MILLION

2004-12-09	LAB international SHARES TRAding ON THE FRANKFURT STOCK EXCHANGE

2004-12-06	LAB INTERNATIONAL TO INITIATE PHASE II TRIAL FOR GHRH

2004-11-24	LAB INTERNATIONAL LICENSES FENTANYL TAIFUN® IN ASIA

2004-08-05	LAB INTERNATIONAL ANNOUNCES SECOND QUARTER 2004 RESULTS

2004-05-25	LAB International REPORTS PROGRESS at AGM

2004-05-12	LAB INTERNATIONAL ANNOUNCES FIRST QUARTER 2004 RESULTS

2004-04-07	LAB International Announces Year End and Fourth Quarter 2003 results

2004-04-01	LAB International Announces Phase I Results for Fentanyl Taifun®

2004-01-12	LAB INTERNATIONAL COMPLETES ACQUISITION OF FOCUS

Home :: Our Company :: Investor Relations :: Products and Technologies :: Business Units :: Contact us :: Site map :: FAQ